Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

NCT07030621 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can improve recovery outcomes in adults who have had an acute ischemic stroke and underwent a procedure called endovascular thrombectomy.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 436 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-07 · est. completion 2028-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07030621 ↗

Description as written by the study sponsor.

The trial will be a randomized, double-blind, controlled, single-center trial. The purpose of this trial is to determine the efficacy and safety of semaglutide in improving neurological outcomes after endovascular thrombectomy for acute ischemic stroke. The patients in the treatment group will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy. The patients in the control group will receive a similar-looking placebo. Patients will be randomized to the treatment or control group by the pharmacy, eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients, further minimizing the bias.

Treatments tested

Semaglutide 0.5 mg Drug

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) analog, which has been found to have neuroprotective effects.
Normal Saline Drug

Normal saline is the placebo drug.

Main thing measured	mRS at 90-days
Sponsor	RenJi Hospital
Conditions studied	Acute Ischemic Stroke
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07030621 ↗